摘要
目的 :探讨参麦注射液对急性心肌梗塞 ( AMI)再灌注性损伤的防治效果。方法 :选择具有溶栓指征的 A MI患者 85例 ,随机分为治疗组与对照组 (分别为 43例与 42例 )。二组均进行尿激酶静脉溶栓治疗。治疗组在用尿激酶前 3 0m in内或同时给予参麦注射液 3 0～ 5 0 m l,1次 /d,连用 10～ 14 d;对照组只用常规治疗。结果 :治疗组发生再灌注性心律失常、严重心功能不全、住院期间死亡率均明显低于对照组 ( P<0 .0 5或 <0 .0 1)。同时 ,治疗组在减少心肌耗氧量、缩小梗塞面积、减少心肌酶的释放和提高左室射血功能等方面均显著优于对照组 ( P<0 .0 5 )。结论 :参麦注射液具有抗 AMI再灌注性损伤的作用。
Objective: To invesgtigate the effect of prevention after thrombolytic therapy in patients with acute myocardial infarction (AMI) with Shen Mai injection. Methods: Choicing 85 AMI patients who adapted thrombolytic therapy, we treated them with urodinase. Then we chose 43 cases to be injected with Shen Mai injection 30～50 ml as therapeutic groups within 30 minutes or at the meantime while given urodinase, and continuly use this dosage once a day for 10～14 days, 42 cases treated with conventional therapy alone as controled group. Results: Reperfusion arrhythmias, serious heart failure and in hospital mortality were all significantly less than the controled group (P<0.01), meanwhile, the therapetic group could decrease the oxygen consumption of myocardium, the area of AMI, the release of the serum myocardium enzyme, and it also could increase the injection function of the left ventride. Conclusion: Shen Mai injection can produce the function of resisting AMI reperfusion injury.
出处
《时珍国医国药》
CAS
CSCD
2000年第5期435-436,共2页
Lishizhen Medicine and Materia Medica Research
